Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Author's Avatar
Jul 11, 2022

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’s previously announced share repurchase program.